News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
129,930 Results
Type
Article (4300)
Company Profile (88)
Press Release (125542)
Multimedia
Podcasts (3)
Webinars (6)
Section
Business (42058)
Career Advice (208)
Deals (6154)
Drug Delivery (13)
Drug Development (17410)
Employer Resources (18)
FDA (1486)
Job Trends (2780)
News (66171)
Policy (3647)
Tag
2024 BioCapital Digital (2)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (3)
2024 Biotech Bay Standard (5)
2024 Biotech Beach Digital (7)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (6)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (4)
2025 Lone Star Bio Digital (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Genetown Standard (1)
2026 Pharm Country Standard (1)
Academia (292)
Adcomms (1)
Allergies (16)
Alliances (11462)
ALS (28)
Alzheimer's disease (330)
Antibody-drug conjugate (ADC) (30)
Approvals (1501)
Artificial intelligence (51)
Autoimmune disease (12)
Automation (4)
Bankruptcy (38)
Best Places to Work (2248)
BIOSECURE Act (14)
Biosimilars (8)
Biotechnology (85)
Bladder cancer (23)
Brain cancer (6)
Breast cancer (73)
Cancer (583)
Cardiovascular disease (17)
Career advice (197)
Career pathing (5)
CAR-T (62)
Cell therapy (176)
Cervical cancer (6)
Clinical research (14155)
Collaboration (264)
Compensation (116)
Complete response letters (2)
COVID-19 (428)
CRISPR (11)
C-suite (106)
Cystic fibrosis (27)
Data (607)
Depression (8)
Diabetes (51)
Diagnostics (698)
Digital health (1)
Diversity, equity & inclusion (8)
Drug discovery (43)
Drug pricing (5)
Drug shortages (2)
Duchenne muscular dystrophy (20)
Earnings (12542)
Editorial (4)
Employer resources (18)
Events (24779)
Executive appointments (278)
FDA (1730)
Featured Employer (13)
Frontotemporal dementia (5)
Funding (226)
Gene editing (26)
Generative AI (4)
Gene therapy (85)
GLP-1 (111)
Government (345)
Guidances (10)
Healthcare (1525)
Huntington's disease (6)
IgA nephropathy (8)
Immunology and inflammation (23)
Indications (11)
Infectious disease (457)
Inflammatory bowel disease (52)
Inflation Reduction Act (1)
Influenza (17)
Intellectual property (36)
Interviews (17)
IPO (2932)
IRA (4)
Job creations (667)
Job search strategy (184)
Kidney cancer (2)
Labor market (9)
Layoffs (38)
Legal (638)
Liver cancer (13)
Lung cancer (44)
Lymphoma (59)
Management (4)
Manufacturing (90)
MASH (10)
Medical device (397)
Medtech (397)
Mergers & acquisitions (3419)
Metabolic disorders (119)
Multiple sclerosis (25)
NASH (1)
Neurodegenerative disease (17)
Neuropsychiatric disorders (3)
Neuroscience (457)
NextGen: Class of 2025 (857)
Non-profit (273)
Northern California (839)
Now hiring (6)
Obesity (60)
Opinion (37)
Ovarian cancer (29)
Pain (21)
Pancreatic cancer (24)
Parkinson's disease (40)
Partnered (4)
Patents (58)
Patient recruitment (30)
Peanut (12)
People (16476)
Pharmaceutical (8)
Phase I (5609)
Phase II (6767)
Phase III (3463)
Pipeline (322)
Policy (26)
Postmarket research (209)
Preclinical (2430)
Press Release (51)
Prostate cancer (21)
Psychedelics (2)
Radiopharmaceuticals (46)
Rare diseases (69)
Real estate (1445)
Recruiting (10)
Regulatory (2970)
Reports (13)
Research institute (298)
Resumes & cover letters (20)
Rett syndrome (1)
RNA editing (1)
RSV (4)
Schizophrenia (12)
Series A (41)
Series B (29)
Service/supplier (2)
Sickle cell disease (11)
Southern California (769)
Special edition (1)
Spinal muscular atrophy (36)
Sponsored (4)
Startups (984)
State (1)
Stomach cancer (2)
Supply chain (18)
Tariffs (7)
The Weekly (3)
United States (6357)
Vaccines (77)
Venture capitalists (7)
Weight loss (22)
Women's health (4)
Worklife (2)
Date
Today (42)
Last 7 days (242)
Last 30 days (735)
Last 365 days (8751)
2025 (2862)
2024 (9142)
2023 (9881)
2022 (11995)
2021 (12643)
2020 (9850)
2019 (6672)
2018 (5275)
2017 (6073)
2016 (5592)
2015 (6439)
2014 (4922)
2013 (4061)
2012 (4400)
2011 (4870)
2010 (4514)
Location
Africa (137)
Alabama (31)
Alaska (1)
Arizona (27)
Arkansas (2)
Asia (8490)
Australia (1997)
California (1949)
Canada (556)
China (112)
Colorado (30)
Connecticut (72)
Delaware (29)
Europe (18536)
Florida (180)
Georgia (28)
Idaho (10)
Illinois (127)
India (4)
Indiana (95)
Iowa (1)
Japan (35)
Kansas (11)
Kentucky (2)
Louisiana (1)
Maine (2)
Maryland (218)
Massachusetts (1419)
Michigan (69)
Minnesota (96)
Missouri (8)
Montana (8)
Nebraska (2)
Nevada (4)
New Hampshire (5)
New Jersey (419)
New Mexico (6)
New York (467)
North Carolina (274)
North Dakota (4)
Northern California (839)
Ohio (39)
Oklahoma (5)
Oregon (5)
Pennsylvania (390)
Puerto Rico (3)
Rhode Island (5)
South America (199)
South Carolina (1)
Southern California (769)
Tennessee (15)
Texas (221)
Utah (18)
Virginia (13)
Washington D.C. (8)
Washington State (325)
Wisconsin (6)
129,930 Results for "imstem biotechnology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001
AgeX Therapeutics, Inc. announced today that ImStem Biotechnology, Inc. (“ImStem”), a biopharmaceutical company developing human embryonic stem cell (ESC)-derived mesenchymal stem cells, has dosed the first U.S. multiple sclerosis (MS) patient with ImStem’s lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA.
November 30, 2021
·
6 min read
Press Releases
Spiderwort Biotechnologies Inc. Announces Status of Biocompatibility Testing for CelluJuve®
April 30, 2025
·
3 min read
Press Releases
Nautilus Biotechnology Reports First Quarter 2025 Financial Results
April 30, 2025
·
8 min read
Press Releases
New tool for cutting DNA: promising prospects for biotechnology
April 15, 2025
·
4 min read
Press Releases
Momentum Biotechnologies Announces Acquisition of OmicScouts
March 5, 2025
·
4 min read
Press Releases
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025
April 28, 2025
·
6 min read
Pharm Country
ImStem Announces First US Multiple Sclerosis Patient Has Been Dosed with its IMS001
ImStem Biotechnology, Inc., a biopharmaceutical company pioneering the development of human embryonic stem cell derived mesenchymal stem cells through a proprietary method using a trophoblast intermediate stage, announced the dosing of the first US multiple sclerosis patient with its lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA.
November 18, 2021
·
3 min read
Press Releases
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results
April 25, 2025
·
2 min read
Press Releases
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
April 23, 2025
·
6 min read
Press Releases
Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025
April 16, 2025
·
1 min read
1 of 12,993
Next
